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Modifi  cations in the FASTPlaqueTB™ test protocol have 
resulted in an increase in the analytical limits of detec-
tion. This study investigated whether the performance of 
a modifi  ed prototype was able to increase the detection 
of smear-negative, culture-positive sputum samples as 
compared to the fi  rst generation FASTPlaqueTB test. 
Modifi  cations to the FASTPlaqueTB did result in in-
creased detection of smear-negative samples, but this was 
associated with a decrease in the specifi  city of the test. 
Before the FASTPlaqueTB can be considered as a viable 
replacement for smear microscopy and culture for the 
identifi  cation of tuberculosis, further work is required to 
resolve the performance issues identifi  ed in this study.
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A NUMBER of rapid diagnostic tests are currently 
available for the diagnosis of tuberculosis (TB), but 
their performance compared to culture is variable. In 
particular, the diagnosis of smear-negative TB is a 
pressing challenge in settings of high human immu-
nodefi  ciency virus (HIV) prevalence, where the pro-
portion of cases of smear-negative pulmonary TB can 
be as high as 61%.1
The fi  rst generation FASTPlaqueTB™ (Biotec Lab-
oratories, Ipswich, UK) test detects approximately 
87% of smear-positive cases and 48–67% of smear-
negative, culture-positive cases within 2 days, and has 
>97% specifi  city.2,3 A modifi  ed FASTPlaqueTB pro-
tocol has been developed that allows up to a 10-fold 
increase in the analytical limit of detection in the test 
in vitro. The modifi  ed FASTPlaqueTB protocol was 
not designed for the sake of cost, time effectiveness 
or practicality, but rather as an attempt to improve 
the sensitivity of the fi  rst generation FASTPlaqueTB. 
This study compared the performance of the FAST-
PlaqueTB test with a modifi  ed prototype protocol for 
the detection of smear-negative, culture-positive spu-
tum samples in a high HIV prevalence community.
METHODS
The study site was an integrated TB-HIV clinic run by 
Médecins Sans Frontières and the provincial govern-
ment of the Western Cape in Khayelitsha Township, 
South Africa, where TB-HIV co-infection is 73%. Spu-
tum samples (n = 196) were collected between 10 
October 2005 and 11 January 2006 from individuals 
presenting with symptoms of pulmonary TB. Smears 
were prepared and stained using auramine-O and ex-
amined by fl  uorescent microscopy (×450 magnifi  ca-
tion). Samples were processed further after transfer to 
a sealable sterile tube to which 5–10 3 mm glass beads 
and 0.5% w/v N-acetyl-l-cysteine (NALC) were added. 
After vortexing for 15 s, the tube was left for 15 min 
at room temperature to allow liquefaction. Samples 
were then transferred to a sterile centrifuge tube to 
which an equal volume of sodium hydroxide-citrate 
was added, and this was left at room temperature for 
another 15 min before neutralisation with 67 mM 
phosphate buffer (pH 6.8). The samples were then 
concentrated by centrifugation (3000 × g for 20 min), 
the supernatant removed and the pellet re-suspended 
in 1.3 ml of phosphate buffer.
Smears were prepared from 50 μl of the suspension; 
0.1 ml was used to inoculate Löwenstein-Jensen (LJ) 
and Middlebrook 7H11 medium slants supplemented 
with nystatin, oxacillin and aztreonam (NOA) anti-
microbial supplement (Biotec).4 Inoculated LJ and 
Middlebrook 7H11 slants were incubated at 37°C 
and growth was recorded at weekly intervals for up 
to 8 weeks. Smears of positive cultures were prepared 
and stained by the Ziehl-Neelsen method. Confi  r-
mation of Mycobacterium tuberculosis complex was 
made by p-nitrobenzoic acid testing.5
Two 0.5 ml aliquots of suspension were transferred 
to separate sterile centrifuge tubes, 15 ml FASTPlaque-
TB Medium Plus was added and the tubes were 
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Twenty-eight FASTPlaqueTB results were invalid 
due to the failure of the controls at day two (most 
likely due to procedural errors). Irrespective of the 
culture result, there were signifi  cantly more positive 
results using the modifi   ed protocol (P  = 0.0016), 
particularly in smear-negative samples (11 [9%] posi-
tives on FASTPlaqueTB as compared to 36 [28.8%] 
using the modifi  ed protocol [P < 0.001]).
The contamination rates of the FASTPlaqueTB 
tests were low (respectively 2.1% and 2.7% for the 
FASTPlaqueTB and the modifi  ed protocol). The per-
formance of the FASTPlaqueTB tests as compared to 
culture is shown in Table. The overall sensitivity of 
the FASTPlaqueTB test was 44.3% (27/61) as com-
pared to 56.7% (38/66) for the modifi  ed protocol. 
Specifi  city was respectively 95.8% (91/95) and 81.1% 
(77/95). There was no statistically signifi  cant differ-
ence in the overall sensitivity between the FASTPlaque-
TB and modifi  ed protocol tests as compared to cul-
ture (P = 0.1283). However, when the performance 
was compared by smear result, a signifi  cant difference 
in sensitivity was found in the smear-negative group 
(FASTPlaqueTB  = 28.6%; modifi  ed  protocol  = 
57.1%; P = 0.0312). There was a statistically signifi  -
cant difference in the overall specifi  city between the 
FASTPlaqueTB and modifi  ed protocol tests as com-
pared to culture (P = 0.0015). When performance 
was compared by smear result, there was a signifi  cant 
difference in specifi  city in the smear-negative group 
(FASTPlaqueTB  = 96.4%; modifi  ed  protocol  = 
78.8%; P = 0.0005). The likelihood ratios (LR) sug-
gest that the FASTPlaqueTB is a better overall pre-
dictor of TB if the test is positive (FASTPlaqueTB LR 
= 10.5; modifi  ed protocol LR = 3).
DISCUSSION
In this study, the performance of the FASTPlaqueTB 
test and a modifi  ed protocol prototype was compared 
c  entrifuged at 3000 × g for 20 min. Supernatants 
were discarded and the resulting pellets suspended in 
1 ml fresh FASTPlaqueTB Medium Plus; 1 ml of sam-
ple was removed from each tube for processing by ei-
ther the FASTPlaqueTB test or the modifi  ed protocol.
The FASTPlaqueTB test was performed according 
to the manufacturers’ instructions.6 The modifi  ed pro-
tocol was based on the FASTPlaqueTB test, with the 
following changes: all FPTB Medium Plus was sup-
plemented with NOA antimicrobial supplement to 
control contamination;7 samples were incubated at 
37ºC for 3 days before testing (to allow more time 
for resuscitation of the mycobacteria); a post-virucide 
amplifi  cation step was included by neutralising the 
Virusol in 45 ml FASTPlaqueTB Medium Plus then 
incubating at 37°C for 4 h to permit increased phage 
infection and release, after which 3 ml of Sensor cells 
were added and the mixture plated in 30 ml of FAST-
PlaqueTB agar.
Results were recorded and analysed using Micro-
soft® Offi  ce Excel (Microsoft, Redmond, WA, USA) and 
AcaStat™ software* (AcaStat, Ashburn, GA, USA).
RESULTS
Of 196 sputum samples collected, eight were discarded 
(three sample containers were empty, two samples 
were from patients aged <16 years, one smear result 
could not be retrieved and two samples were from pa-
tients on TB treatment). Smear microscopy indicated 
that 72.9% (137/188) of the samples were smear-
negative, 6% (11/188) were scanty positive, 3.7% 
(7/188) were 1+ positive, 3.7% (7/188) were 2+ 
positive and 13.8% (26/188) were 3+ positive.7 The 
combined culture contamination rate was 7% (13/ 
188), 57.5% (108/188) of the samples were culture-
negative, and 35.6% (67/188) were culture-positive.
* http://www.acastat.com
Table  Performance of the FASTPlaqueTB and modiﬁ  ed protocol tests as compared to the 











  Sensitivity 44.3 (31.8–56.8)   57.6 (40.7–74.5) 28.6 (11.9–45.3)
 Speciﬁ  city 95.8 (91.7–99.8)   91 (74.1–100) 96.4 (92.4–100)
  Negative predictive value   0.73 (0.64–0.8)     0.42 (0.27–0.57)   0.8 (0.73–0.87)
  Positive predictive value   0.87 (0.82–0.92)     0.95 (0.89–1.0)   0.73 (0.65–0.81)
  Positive likelihood ratio 10.5 (3.9–28.6)     6.33 (0.96–42)   8.0 (2.3–28.1)
  Negative likelihood ratio   0.58 (0.46–0.73)     0.47 (0.3–0.7)   0.74 (0.58–0.94)
Modiﬁ  ed protocol
  Sensitivity 56.7 (45.8–69.7)   57.9 (42.2–73.6) 57.1 (38.8–75.4)
 Speciﬁ  city 81.1 (73.2–89) 100 78.8 (70.1–87.5)
  Negative predictive value   0.73 (0.64–0.8)     0.39 (0.65–0.8)   0.85 (0.78–0.92)
  Positive  predictive  value  0.68  (0.61–0.75)   1.0  0.47  (0.39–0.56)
  Positive  likelihood  ratio  3.0  (1.9–3.8)         ∞ (0.77–∞)  2.7  (1.6–4.5)
  Negative likelihood ratio   0.52 (0.39–0.71)     0.42 (0.29–0.61)   0.54 (0.35–0.85)
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to culture (gold standard) in a setting of high TB-HIV 
co-infection. In all, 72.9% of samples were found to 
be smear-negative, which is higher than previously 
reported,1 but not surprising given the high rate of 
TB-HIV co-infection in the study population. The 
overall sensitivity of FASTPlaqueTB was approxi-
mately 20% lower than previously reported,2,3,8 and 
the sensitivity using the modifi  ed protocol was not, 
as in vitro results suggested, signifi  cantly better. Pos-
sible explanations for the low sensitivities include the 
detrimental effect of the modifi  ed decontamination 
method on the mycobacteria (including prolonged 
exposure to NALC), splitting of the sample resulting 
in insuffi  cient quantity of mycobacteria in the sam-
ple, or an HIV-associated phenomenon.
In the smear-negative, culture-positive group, there 
was a 28.5% increase in sensitivity using the modi-
fi  ed prototype. However, this increase was associated 
with a signifi  cant decrease in the specifi  city of the mod-
ifi  ed prototype test. The specifi  city of FASTPlaque-
TB was similar to that observed in other studies,2,3,8 
suggesting that the low specifi   city of the modifi  ed 
prototype is not associated with sample decontami-
nation (common to both protocols), but is more likely 
to be due to non-specifi  c phage replication during the 
post-virucide amplifi  cation or inadequate neutralisa-
tion of phage particles.
It is concluded that further work is required to im-
prove the specifi  city of the test using the modifi  ed pro-
tocol. Furthermore, the poor performance of the FAST-
PlaqueTB test in this study needs to be resolved before 
investigation of a modifi  ed protocol can be made.
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RÉSUMÉ
Les modifi  cations du protocole du test FASTPlaqueTB™ 
ont entraîné une élévation de la limite analytique de dé-
tection. Cette étude cherche dans quelle mesure la per-
formance d’un prototype modifi  é est apte à augmenter 
la détection d’échantillons à bacilloscopie négative et à 
culture positive par comparaison avec le test FASTPlaque-
TB de première génération. Les modifi  cations du FAST-
PlaqueTB ont entraîné une augmentation de la détec-
tion des échantillons à bacilloscopie négative, mais sont 
en association avec une diminution de la spécifi  cité du 
test. Avant de considérer le FASTPlaqueTB comme un 
remplacement viable de l’examen microscopique direct et 
de la culture pour l’identifi  cation de la tuberculose, des 
travaux complémentaires s’imposent pour résoudre les 
problèmes de performance identifi  és dans cette étude.
RESUMEN
Las modifi   caciones introducidas al protocolo de la 
prueba FASTPlaqueTB™ tuvieron como consecuencia 
un mayor límite de detección del método. En el presente 
estudio se investigó si, comparado con el protocolo ori-
ginal, un prototipo modifi  cado de la prueba mejoraba la 
detección de bacilos acidorresistentes en muestras con 
examen microscópico y cultivo negativos. Las modifi  ca-
ciones condujeron en efecto a una mayor detección de 
muestras con frotis negativo, pero este efecto se asoció 
con una disminución de la especifi  cidad de la prueba. 
Antes de considerar la FASTPlaqueTB como sucedáneo 
viable de la microscopia y el cultivo en la detección de 
Mycobacterium tuberculosis, se precisan nuevos traba-
jos que resuelvan los problemas del desempeño de la 
prueba encontrados en el presente estudio.